Pascal J Bonaventure

US Patent:

7893197, Feb 22, 2011

Filed:

Aug 25, 2005

Appl. No.:

11/660883

Inventors:

Pascal Bonaventure - San Diego CA, US
Chester Kuei - San Diego CA, US
Changlu Liu - San Diego CA, US
Timothy W. Lovenberg - San Diego CA, US
Steven W. Sutton - Carlsbad CA, US

Assignee:

Janssen Pharmaceutica N.V. - Beerse

International Classification:

A61K 38/00
C07K 14/64

US Classification:

530300, 530325, 530350

Abstract:

Chimeric polypeptides of relaxin-3, prepropolypeptides thereof, polynucleotides encoding such polypeptides, and associated expression vectors and host cells are described. The polypeptides may be used to prepare receptor-ligand complexes with GPCR135 or GPCR142, which may be used in assay methods.

US Patent:

8183239, May 22, 2012

Filed:

Oct 27, 2006

Appl. No.:

11/553556

Inventors:

Pascal Bonaventure - San Diego CA, US
Nicholas I. Carruthers - Poway CA, US
Wenying Chai - San Diego CA, US
Curt A. Dvorak - San Diego CA, US
Jill A. Jablonowski - San Diego CA, US
Dale A. Rudolph - San Diego CA, US
Mark Seierstad - San Diego CA, US
Chandravadan R. Shah - San Diego CA, US
Devin M. Swanson - La Jolla CA, US
Victoria D. Wong - San Diego CA, US

Assignee:

Janssen Pharmaceutica NV - Beerse

International Classification:

A61K 31/495
A61K 31/496
A61K 31/5377
C07D 211/34
C07D 211/58
C07D 213/56
C07D 295/15
C07D 401/04
A61K 31/451
A61K 31/454
C07D 401/12
C07D 417/12

US Classification:

5142358, 51425301, 51425313, 51425403, 5142541, 51425411, 51425503, 544121, 544360, 544364, 544367, 544372, 544374, 544377, 544379, 544393, 544238, 544295, 544322, 546194, 546208, 546210, 546234, 546257, 546265, 5462767, 546209, 548453

Abstract:

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep/wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility. The compounds of the present invention are of the formula.

US Patent:

20020156038, Oct 24, 2002

Filed:

Oct 4, 2001

Appl. No.:

09/971900

Inventors:

Pascal Bonaventure - San Diego CA, US
Hongqing Quo - San Diego CA, US
Xuejun Liu - San Diego CA, US
Fredrik Kamme - San Diego CA, US
Bernhard Meurers - La Jolla CA, US
Josepha Leysen - Oud-Turnhout, BE
Margot Bakker - Breda, NL

International Classification:

A61K048/00
C12Q001/68
C12M001/34

US Classification:

514/044000, 435/006000, 435/287200

Abstract:

Implementing gene expression to study drug action in the central nervous system is complicated by functional heterogeneity because of the existence of many different neuronal subtypes within the mammalian brain. The integration of laser capture microdissection (LCM) and RNA amplification with cDNA microarray technology allows for large-scale gene expression analysis at cellular level. Using this approach, we have generated gene expression profiles of imipramine, a reference antidepressant, and a new putative antidepressant, novelR1 in several laser-captured brain nuclei (locus coeruleus, dorsal raphe, hypothalamic paraventricular nucleus and hippocampus) of rats subjected to the chronic mild stress model (CMS) of depression.

US Patent:

20080131913, Jun 5, 2008

Filed:

Jan 13, 2006

Appl. No.:

11/795278

Inventors:

Pascal Bonaventure - San Diego CA, US
Changlu Liu - San Diego CA, US
Timothy W. Lovenberg - San Diego CA, US
Diane Nepomuceno - San Diego CA, US

International Classification:

G01N 33/53
C07K 14/00
C12N 15/00
G01N 33/567
C12N 5/06

US Classification:

435 721, 530350, 4353201, 435325, 435 78

Abstract:

Canine 5-hydroxytryptamine 2 receptor materials are described, including polypeptides corresponding to SEQ ID NOs:8 and 10 and polynucleotides expressing them corresponding to SEQ ID NOs:7 and 9. Such materials are useful as reagents in drug screening assays to identify compounds having 5-HTreceptor-modulating activity.

US Patent:

20090275563, Nov 5, 2009

Filed:

Oct 18, 2006

Appl. No.:

12/375393

Inventors:

Pascal Bonaventure - San Diego CA, US

International Classification:

A61K 31/55
A61K 31/437
A61K 31/517
A61K 31/519
A61K 31/505
A61K 31/454
A61K 31/4439
A61K 31/496
A61K 31/5375
A61P 25/00
A61P 1/00
A61P 13/02
A61P 3/00
A61P 9/00

US Classification:

514215, 514300, 5142581, 5142651, 514256, 514326, 514339, 51425411, 51425405, 514217, 5142392, 5142641

Abstract:

Patients suffering from serotonin-mediated diseases or conditions, such as depression, may be treated by administering an effective combined amount of a 5-HT7 receptor antagonist and a serotonin reuptake inhibitor.